{"id":961263,"date":"2026-05-12T07:17:00","date_gmt":"2026-05-12T11:17:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/"},"modified":"2026-05-12T07:17:00","modified_gmt":"2026-05-12T11:17:00","slug":"atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/","title":{"rendered":"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million"},"content":{"rendered":"

<\/p>\n

ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million<\/b><\/p>\n

HAYWARD, Calif.–(BUSINESS WIRE<\/a>)–
\nPulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences\u2019 common stock through its at-the-market equity offering program (ATM) during the Company\u2019s designated trading window.<\/p>\n

\nIn total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences\u2019 common stock for an aggregate purchase price of approximately $13.3 million.<\/p>\n

About Pulse Biosciences\u00ae<\/b><\/p>\n

\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company\u2019s proprietary nPulse\u2122 technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.<\/p>\n

\nPulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and\/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260512191223\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
Pulse Biosciences, Inc.
\n
Jon Skinner, CFO
\n
IR@pulsebiosciences.com<\/a><\/p>\n

\nOr<\/p>\n

\nGilmartin Group
\n
Philip Trip Taylor
\n
415.937.5406
\n
philip@gilmartinir.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Medical Devices Health Health Technology Cardiology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million HAYWARD, Calif.–(BUSINESS WIRE)– Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences\u2019 common stock through its at-the-market equity offering program (ATM) during the Company\u2019s designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences\u2019 common stock for an aggregate purchase price of approximately $13.3 million. About Pulse Biosciences\u00ae Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company\u2019s … <\/p>\n

Continue reading “ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-961263","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million HAYWARD, Calif.–(BUSINESS WIRE)– Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences\u2019 common stock through its at-the-market equity offering program (ATM) during the Company\u2019s designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences\u2019 common stock for an aggregate purchase price of approximately $13.3 million. About Pulse Biosciences\u00ae Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company\u2019s … Continue reading "ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T11:17:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million\",\"datePublished\":\"2026-05-12T11:17:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/\",\"name\":\"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-05-12T11:17:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/","og_locale":"en_US","og_type":"article","og_title":"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million - Market Newsdesk","og_description":"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million HAYWARD, Calif.–(BUSINESS WIRE)– Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences\u2019 common stock through its at-the-market equity offering program (ATM) during the Company\u2019s designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences\u2019 common stock for an aggregate purchase price of approximately $13.3 million. About Pulse Biosciences\u00ae Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company\u2019s … Continue reading \"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-12T11:17:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million","datePublished":"2026-05-12T11:17:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/","name":"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-05-12T11:17:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260512191223r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ATM Equity Purchases by Pulse Biosciences\u2019 Co-Chairmen Total Approximately $13.3 Million"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=961263"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/961263\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=961263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=961263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=961263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}